ApoB vs LDL Cholesterol: The Better Heart Disease Marker in 2026
Mendelian randomisation and discordance analyses now make ApoB — not LDL-C — the most accurate single number for atherosclerotic risk. Most people, and most doctors, still are not measuring it.
Atherosclerotic cardiovascular disease (ASCVD) is still the leading cause of death globally and the single biggest threat to healthspan. The lipid number most people get on a standard panel — LDL-cholesterol — is a useful proxy, but it is no longer the best one we have. Apolipoprotein B (ApoB) is.
If you are serious about longevity and you have ever had a routine cholesterol panel, you almost certainly should add ApoB to your next blood draw. Here is why.
What ApoB actually is Every atherogenic lipoprotein particle in your bloodstream — LDL, VLDL, IDL, lipoprotein(a) and chylomicron remnants — carries exactly one molecule of apolipoprotein B-100 (or B-48 for chylomicrons) on its surface. Measure ApoB and you have measured the total count of particles that can drive a plaque into an artery wall. LDL-C, by contrast, measures the cholesterol *inside* one type of particle. Two people with identical LDL-C can carry very different numbers of particles, and it is the particle count that drives risk.
This is not a niche opinion. The European Atherosclerosis Society's 2023 consensus statement on ApoB (Sniderman et al., European Heart Journal) concluded that ApoB is causally and quantitatively related to ASCVD across the entire range, and that it should replace LDL-C as the primary lipid target in clinical practice. Multiple large Mendelian randomisation studies — which use genetic variants as natural randomised experiments — show the same thing: when LDL-C and ApoB disagree, ApoB wins as the better predictor of heart attack and stroke.
Why LDL-C can mislead you LDL-C and ApoB usually move together, but in roughly 1 in 5 adults they do not. The two most common discordance patterns are:
- **High ApoB, normal LDL-C.** Common in insulin resistance, metabolic syndrome, type 2 diabetes and high-triglyceride states. The particles are small, dense and numerous; cholesterol content per particle is low, so LDL-C looks fine while particle number is dangerously high.
- **Normal ApoB, high LDL-C.** Less common, but seen in some genetic patterns and on certain diets. Particles are large, fluffy and fewer; risk is lower than the LDL-C number suggests.
If you only ever look at LDL-C, the first group — which includes a huge fraction of people with central adiposity and prediabetes — are being told they are fine when they are not. This is one reason why our biomarker insights tool explicitly asks for ApoB.
Target ranges for longevity Population averages are not longevity targets. A few useful anchors:
- **Average US adult ApoB**: ~100 mg/dL
- **Conventional treatment threshold**: ~90 mg/dL
- **Secondary prevention (post-event)**: <65 mg/dL
- **Longevity-aggressive targets** (used by clinicians like Peter Attia): 30–60 mg/dL, depending on family history and other risk factors
Lifetime ApoB exposure — concentration multiplied by years — is what drives plaque burden. Lowering ApoB earlier matters disproportionately more than lowering it later. A 50-year-old with ApoB of 90 mg/dL since their twenties has already deposited far more atherogenic cholesterol into their arteries than someone who reaches the same number at 70.
How to test it ApoB is a cheap, well-standardised immunoturbidimetric assay. In the US it typically costs $15–40 added to a lipid panel; in the UK it is part of most private "advanced lipid" panels. You do not need to fast for a useful ApoB reading, although fasting still helps with triglycerides on the same draw. Re-test 8–12 weeks after any meaningful change in diet, body composition or medication.
If you can, also measure **lipoprotein(a)** once in your life. Lp(a) is genetically determined, does not respond meaningfully to lifestyle, and is independently atherogenic. A high Lp(a) (>50 mg/dL or >125 nmol/L) means your ApoB target should be more aggressive.
How to lower ApoB The interventions are unsexy and well established. Stack them, do not rotate them.
- **Reduce saturated fat to roughly 6–7% of calories.** This is the single biggest dietary lever. Swap butter, fatty cuts of red meat and tropical oils for olive oil, nuts, fatty fish and plant proteins.
- **Add soluble fibre, 10–25 g/day.** Oats, psyllium, beans and barley lower ApoB by 5–15%.
- **Lose visceral fat.** Even modest reductions in waist circumference move ApoB and triglycerides quickly. Our zone 2 cardio guide covers the most efficient training pattern.
- **Resistance training and improved insulin sensitivity.** Both shift the LDL particle distribution towards larger, fewer particles and lower ApoB.
- **Berberine, 500 mg 2–3x/day with meals.** Modest but real ApoB-lowering effect, mostly via PCSK9 expression. See our berberine deep dive.
- **Statins, ezetimibe, bempedoic acid, PCSK9 inhibitors.** When lifestyle alone cannot reach target, the pharmacology is the safest, best-studied set of drugs in medicine. The choice between them is a clinician conversation.
Where ApoB fits in the wider longevity picture ApoB is the most important single cardiovascular number, but it is not the only one. Blood pressure, fasting insulin, HbA1c, hsCRP, ApoB *and* Lp(a) form the practical cardiometabolic dashboard. The interactions matter: high ApoB on a background of insulin resistance and hypertension is far more dangerous than the same ApoB in a lean, well-trained person. Many readers find a structured way to prioritise these markers helpful — that is exactly what our [biomarker insights tool](/ai-tools/biomarker-insights) and the broader [protocols library](/protocols) are designed for.
For the broader cardiometabolic context, the GLP-1 longevity write-up covers how the new generation of metabolic drugs is reshaping ApoB targets, and the NAD+ piece covers the mitochondrial side of the same equation.